Project Grant R21CA296470
Award Date 8/15/25
Completion Date 7/31/27
Dollars Obligated $427K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...
- The National Cancer Institute (NCI) awarded a $712,735 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Southern California (USC) on June 1, 2025. This grant will fund a Phase II clinical trial to evaluate the efficacy of a combination therapy using the novel agent SEPHB4-HSA, an EphrinB2 inhibitor, and the PD-1 antibody Pembrolizumab in urothelial carcinoma (bladder cancer) patients whose tumors express EphrinB2 and have low/non-expressing Nectin4...
- The University of Southern California was awarded a $613,220 Project Grant under the National Cancer Institute's Cancer Cause and Prevention Research (CFDA 93.393) program. The grant, which runs from February 1, 2025 to January 31, 2030, will fund research to investigate the contribution of germline copy number variations to the susceptibility of aggressive prostate cancer in men of African and European ancestry. The project aims to leverage existing genome-wide association study, whole-exome...
- The University of Southern California received a $194,013 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop a new tool to treat small cell lung cancer (SCLC). The project aims to generate a monoclonal antibody specific for the isoaspartylated form of the ELAVL4 protein, which is expressed on the surface of SCLC tumors and can induce an immune response in some patients. This antibody-based approach seeks to leverage...
- The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
- The University of Southern California (USC) received a $704,882 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to define the genetic factors underlying familial prostate cancer in African American (AA) men. The project aims to develop improved risk prediction models that incorporate polygenic risk scores, pathogenic variants, and family history of prostate cancer for the AA population. By leveraging existing...
- The University of California, Los Angeles (UCLA) received a $649,181 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) on August 8, 2025. The grant supports UCLA's research to develop enhanced sample preparation reagents and custom proteomics platforms to pinpoint covalent labeling sites that alter protein thermal stability, which can help prioritize high-value therapeutic targets for further mode of action studies. This work builds on...
- The University of Chicago was awarded a $230,010 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct research on uncovering the cellular and molecular drivers behind the aggressive metastatic potential of small cell lung cancer (SCLC). The project aims to leverage innovative human pluripotent stem cell-derived models of SCLC to gain deeper insights into this complex issue. By examining cell behavior in both primary tumors and...
- The University of North Carolina at Chapel Hill (UNC-CH) received a $514,582 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct research on "Targeting APOBEC3-Induced Squamous Differentiation in Bladder Cancer". The award began on March 1, 2025 and is set to conclude on February 28, 2030. The research aims to investigate the role of APOBEC3 enzymes in bladder cancer initiation and progression,...
- The University of California, San Diego (UCSD) was awarded a $2,984,495 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop and clinically validate a comprehensive liquid biopsy platform for advanced renal cell carcinoma (RCC) patients. The key objectives are to: 1) validate early on-treatment circulating tumor cell (CTC) dynamics as prognostic biomarkers, 2) validate early on-treatment CTC dynamics as predictive biomarkers for...